Core Viewpoint - The company Tongyuan Kang Pharmaceutical-B (02410) announced a capital increase agreement that will dilute its ownership in Tongyuan Kang Biotechnology from approximately 57.14% to 39.03% after the completion of the capital increase, which is expected to enhance operational funding for the biotechnology firm [1] Group 1: Capital Increase Details - The total consideration for the capital increase is approximately RMB 83.5 million [1] - The registered capital of Tongyuan Kang Biotechnology will increase from RMB 14 million to approximately RMB 20.49 million [1] - The agreement involves existing shareholders including the company itself and several investment firms [1] Group 2: Company Operations and Strategy - Tongyuan Kang Biotechnology is a biopharmaceutical company focusing on dual antibodies, triple antibodies, and ADCs, operating independently from the core business of the group [1] - The capital increase is expected to provide necessary operational funds for Tongyuan Kang Biotechnology, which is in an early-stage startup phase and anticipates significant funding needs before achieving commercialization [1] - This transaction allows the group to concentrate its resources on other operational aspects while retaining significant equity and involvement in Tongyuan Kang Biotechnology [1]
同源康医药-B(02410)：同源康生物将获增资8350万元